Day 2 :
Keynote Forum
Gianni Pertici
Industrie Biomediche Insubri SA, Switzerland
Keynote: Xenohybrid scaffolds for bone regeneration
Biography:
Hard tissue regeneration is a complex phenomenon that involves intricate interplays within the patient autologous cells and the grafted material. Autologous bone remains the gold standard as it naturally presents appropriate mechanical and biological characteristics and avoids rejection or disease transmission risks. Nevertheless, a major limitation is represented by the available volume for removal from patient’s body alternative sides. A valid alternative, not limited in this sense, is represented by hybrid composite scaffolds. Taking advantage of porous and interconnected natural structures, such as the one of xenogeneic cancellous bone, it is possible to improve their characteristics via combination with other functional components. This way, mechanical and biological performance, similar to the one of autografts, can be obtained. In this contribution, we present a newly developed material (SmartBone®) which is composed of bovine bone, polymer and proteins. The mineral matrix provides adequate solid framework and open porosity, ensuring cells proliferation. The bioresorbable polymer reinforces the main structure and the collagen, exposing RGD sequences, stimulates blood cell’s adhesion. This way, this innovative scaffold is osteoconductive and osteoinductive, promoting complete remodeling to mature bone after 8-12 months, as supported by histological data. Since its launch on the market, this technology was successfully used on roughly 60,000 patients worldwide, covering dental and orthopedic applications. A relevant example of the many destination of use is visible in Figure 1, in which a customized solution for hip reconstruction after tumor removal is presented. During surgery, the piece was perfectly located inside the gap and firmly fixed with osteosynthesis titanium screws. Surgery was faster with respect to the standard procedures and very precise, allowing obtaining very satisfactory results both in terms of anatomical reconstruction and functionality. The post-operative follow-up recorded no issues and proceeded optimally. Control CT scan showed good osteo integration and massive volume stability (>95%).
Abstract:
Gianni Pertici has completed his Master’s degree in Chemical Engineering from the University of Pisa and PhD in Biomaterials at the Dept. of Chemistry of University of Pisa and at King’s College of London. His studies were focused on Processing Engineering and Material Properties especially for the biomedical field. He has worked as a R&D director of Swiss Stem Cell Bank and founded IBI a Swiss Biotech company. He is Author in more than 30 papers, 3 books and single inventor of 2 patents. He was also the Researcher at the University of Applied Science of Southern Switzerland from 2010 until 2018.
- Cell Therapy | Stem Cell Therapy | Cancer Therapy | Wound Care | 3D Culture | Bone Tissue Engineering | Biomaterials
Location: Scandic Jarvenpaa | Helsinki, Finland
Session Introduction
Claire Saucourt
CellProthera, France
Title: Expanded CD34+ cells for cardiac cell therapy
Biography:
Claire after a Phd. in cell biology, she joined the team of founders of CellProthera in 2009 and participated with her team to scientific works including the design and development of the StemXpand and the surrounding process. As project manager, and in collaboration with the CMO, she is an active element in the preparation of international clinical trials and participates to discussions with various regulatory authorities. In collaboration with the CDO, she is currently involved in the development of the future commercial device and the complete characterization of the process.
Abstract:
Background: We previously demonstrated that intra-cardiac delivery of autologous peripheral blood-CD34+ stem cells, mobilized by granulocyte-colony stimulating factor (G CSF) and collected by leukapheresis after myocardial infarction, structurally and functionally repaired the damaged myocardial area. When used for cardiac indication, CD34+ cells are now considered as ATMP (Advanced Therapy Medicinal Product). We have industrialized their production by developing an automated device for ex-vivo CD34+ stem cell expansion, starting from a whole blood sample. Method: Blood samples were collected from healthy donors after G-CSF mobilization. Manufacturing procedures included: (1) isolation of total nuclear cells (2) CD34+ immunoselection (3) expansion and cell culture recovery in the device and (4) expanded CD34+cell immunoselection and formulation. The assessment of CD34+ cell counts, viability and immunophenotype and sterility tests were performed as quality tests. Result: We established graft acceptance criteria and performed validation processes in three cell therapy centers (CTCs). 59.4±36.8×106 viable CD34+ cells were reproducibly generated as the final product from 220 mL whole blood containing 17.1±8.1x106 viable CD34+ cells. CD34+ identity, genetic stability and telomere length were consistent with those of basal CD34+ cells. Gram staining and mycoplasma and endotoxin analyses were negative in all cases. We confirmed the therapeutic efficacy of both CD34±cell categories in experimental AMI (Acute Myocardial Infarct) in immuno-deficient rats during pre-clinical studies. Discussion: This reproducible, automated, and standardized expansion process produces high numbers of CD34+ cells corresponding to the approved ATMP and paves the way for a phase I/IIb study in AMI, which is currently recruiting patients.
Biography:
Claire after a Phd. in cell biology, she joined the team of founders of CellProthera in 2009 and participated with her team to scientific works including the design and development of the StemXpand and the surrounding process. As project manager, and in collaboration with the CMO, she is an active element in the preparation of international clinical trials and participates to discussions with various regulatory authorities. In collaboration with the CDO, she is currently involved in the development of the future commercial device and the complete characterization of the process.
Abstract:
Background: We previously demonstrated that intra-cardiac delivery of autologous peripheral blood-CD34+ stem cells, mobilized by granulocyte-colony stimulating factor (G CSF) and collected by leukapheresis after myocardial infarction, structurally and functionally repaired the damaged myocardial area. When used for cardiac indication, CD34+ cells are now considered as ATMP (Advanced Therapy Medicinal Product). We have industrialized their production by developing an automated device for ex-vivo CD34+ stem cell expansion, starting from a whole blood sample. Method: Blood samples were collected from healthy donors after G-CSF mobilization. Manufacturing procedures included: (1) isolation of total nuclear cells (2) CD34+ immunoselection (3) expansion and cell culture recovery in the device and (4) expanded CD34+cell immunoselection and formulation. The assessment of CD34+ cell counts, viability and immunophenotype and sterility tests were performed as quality tests. Result: We established graft acceptance criteria and performed validation processes in three cell therapy centers (CTCs). 59.4±36.8×106 viable CD34+ cells were reproducibly generated as the final product from 220 mL whole blood containing 17.1±8.1x106 viable CD34+ cells. CD34+ identity, genetic stability and telomere length were consistent with those of basal CD34+ cells. Gram staining and mycoplasma and endotoxin analyses were negative in all cases. We confirmed the therapeutic efficacy of both CD34±cell categories in experimental AMI (Acute Myocardial Infarct) in immuno-deficient rats during pre-clinical studies. Discussion: This reproducible, automated, and standardized expansion process produces high numbers of CD34+ cells corresponding to the approved ATMP and paves the way for a phase I/IIb study in AMI, which is currently recruiting patients.
Biography:
Omid Panahi has completed his Graduation from Centro Escolar University on Doctor of Dental Medicien and MSc in Oral and Maxillofacial surgery from Yeditepe University, Istanbul, Turkey. He has published more than 40 papers in reputed journals and has been serving as an Editorial Board Member of ISI journals.
Abstract:
Stem cells are unique cells and reproducible cells that can be useful as a good alternative to future therapies in the field of dentistry as well as oral surgeries in the mouth. The aim of the present study was to investigate the stem cells type, characteristics and benefits of the stem cells and its role in modern dentistry. With online search about stem cells and regenerative dentistry in dental and medicine journals to retrieve clinical and experimental studies, case reports and review articles by using keywords: dental stem cells, future dentistry. The future of modern dentistry can be regenerative stem cell-based for oral and dental care, which will be used by patients own stem cells to treat the disease.
Pamela Klecki
Karolinska Institute, Sweden
Title: Heterogeneity of sympatho-adrenal system reveals new possible origin of neural-crest derived tumors
Biography:
Pamela Klecki has completed her Graduation in from University of Vienna. She is currently pursuing her Masters in both Tissue Engineering and Regenerative Medicine at the University of Applied Sciences Technikum Wien and in the Experimental and Medical Biosciences at Linkoping University in Sweden
Abstract:
Adrenergic chromaffin cells of the adrenal medulla are generated through recruitment of nerve- associated neural crest-derived cells termed Schwann cell precursors (SCPs). The present study evaluates the effect of serotonin precursor (5-HTP) on survival and proliferation of neural crest derived progenitors into chromaffin cells on E13.5 explants derived from C57BL/6 wild type mice. We also investigate whether serotonin (5-HT) enhances neurite outgrowth and proliferation in non differentiated rat pheochromocytoma cells (PC12), which originate from chromaffin cells. Here we report that treatment with serotonin precursors resulted in a significant decrease of proliferating tyrosine hydroxylase positive (TH+) cells in the adrenal gland (AG). In addition, we demonstrated that serotonin enhances neurite outgrowth in non differentiated cells. The preliminary data indicate the potential of serotonin to function as a new molecular target for neural crest-derived tumors as pheochromocytoma.